



MAY 03 2002

Page 1 of 1

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/970,971	10/04/2001	Muthiah Manoharan	ISIS-4789

CONFIRMATION NO. 3195

FORMALITIES LETTER



OC000000007579212

Woodcock Washburn LLP
46th Floor
One Liberty Place
Philadelphia, PA 19013

REF ID: A6512

MAR 11 2002

Witnosc i wspanialosc Kutz w jego dziele "Sztuka"

Date Mailed: 03/05/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- **For Rules Interpretation, call (703) 308-4216**
 - **To Purchase PatentIn Software, call (703) 306-2600**
 - **For PatentIn Software Program Help, call (703) 306-
patin21help@uspto.gov or patin3help@uspto.gov**

~~mailed~~ RECEIVED
MAR 11 2002
DOCKET DEPT.
~~WWKMN~~

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

OS-DT-S

03CD
BDA-STQ

T
PATENT

DOCKET NO.: ISIS-4789

MAY 03 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In Re Application of:

Manoharan et al.

Serial No.: 09/970,971

Group Art Unit: Not Yet Assigned

Filing Date: October 4, 2001

Examiner: Not Yet Assigned

For: Oligonucleotides Having DNA Form And B-DNA Form Conformational Geometry

EXPRESS MAIL LABEL NO: EL 926701606 US
DATE OF DEPOSIT: May 3, 2002

EL 926701606 US

U. S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, Virginia 22202

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE**

In response to the "Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated 4/5/2002, a response to which is due 5/5/2002, enclosed herewith is:

- Statement to Support Filing and Submission in Accordance with 37 CFR §§1.821 through 1.825;
- Substitute pages of the Sequence Listing;
- Substitute copy of the computer readable form of Sequence Listing;
- Amendment Directing Entry of Sequence Listing into Specification is attached
- Copy of Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- Other:

- Request is hereby made under 37 CFR 1.136(a) to extend the time for response to the Notice to File Missing Parts of Application of @@ to and through @@, comprising an extension of the shortened period of @@ months:


	SMALL ENTITY		NOT SMALL ENTITY	
	RATE	FEE	RATE	FEE
<input type="checkbox"/> ONE MONTH EXTENSION OF TIME	\$55	\$	\$110	\$
<input type="checkbox"/> TWO MONTH EXTENSION OF TIME	\$200	\$	\$400	\$
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME	\$460	\$	\$720	\$
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME	\$720	\$	\$1440	\$
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME	\$980	\$	\$1960	\$
TOTAL FEE DUE				

Applicant(s) has/have not been notified that the requested extension will not be permitted. The present application is not involved in an interference declared pursuant to 37 CFR 1.207.

Total fee required \$@@


The Commissioner is hereby authorized to charge any underpayment associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in duplicate.

Date: May 3, 2002



Emma R. Dailey
Registration No. 48,491

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



DOCKET NO.: ISIS-4789

PATENT

8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Manoharan et al.

Serial No.: 09/970,971

Group Art Unit: Not yet assigned

Filing Date: October 4, 2001

Examiner: Not yet assigned

For: Oligonucleotides Having DNA Form And B-DNA Form Conformational Geometry

EXPRESS MAIL LABEL NO: EL 926701606 US
DATE OF DEPOSIT: May 3, 2002

U. S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, Virginia 22202


**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825**

- I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
- I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
- I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
- I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.



I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Date: May 3, 2002



Emma R. Dailey
Registration No. 48,491

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2001 WW